Evidence map›Paper›PMID 34943745›Full record

ArticleAntibiotics (Basel, Switzerland)2021

Genomic Insights into the Distribution and Phylogeny of Glycopeptide Resistance Determinants within the

Andrés Andreo-Vidal, Elisa Binda, Victor Fedorenko, Flavia Marinelli, Oleksandr Yushchuk

Open access · goldAbstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Occurrence ofGenes · 2022
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Andrés Andreo-VidalDepartment of Biotechnology and Life Sciences, University of Insubria, 21100 Varese, Italy.
Elisa BindaDepartment of Biotechnology and Life Sciences, University of Insubria, 21100 Varese, Italy.ORCID 0000-0001-9305-4451
Victor FedorenkoDepartment of Genetics and Biotechnology, Ivan Franko National University of Lviv, 79005 Lviv, Ukraine.
Flavia MarinelliDepartment of Biotechnology and Life Sciences, University of Insubria, 21100 Varese, Italy.ORCID 0000-0001-9195-6777
Oleksandr YushchukDepartment of Biotechnology and Life Sciences, University of Insubria, 21100 Varese, Italy.
University of Insubria · ITLviv University · UA

Funding

Fondo di Ateneo per la Ricerca FAR2019 FAR2020Ministry of Education and Science of Ukraine BG-09F
6 · The paper itself

Abstract

The spread of antimicrobial resistance (AMR) creates a challenge for global health security, rendering many previously successful classes of antibiotics useless. Unfortunately, this also includes glycopeptide antibiotics (GPAs), such as vancomycin and teicoplanin, which are currently being considered last-resort drugs. Emerging resistance towards GPAs risks limiting the clinical use of this class of antibiotics-our ultimate line of defense against multidrug-resistant (MDR) Gram-positive pathogens. But where does this resistance come from? It is widely recognized that the GPA resistance determinants-

Indexed as

antibiotic resistanceglycopeptide antibioticsmultidrug resistancevan genes

Identifiers

PMID34943745
PMCPMC8698665
OpenAlexW4200185813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.